Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05874466 · ClinicalTrials.gov registry record

SenseToKnow Autism Screening Device Validation Study

A clinical trial of Autism Spectrum Disorder and Autism, sponsored by Duke University.

Recruiting
Registry status
350
Enrollment target
1
Study location

NCT05874466 is a study of Autism Spectrum Disorder and Autism that is actively recruiting participants, run by Duke University. The registered enrollment target is 350 participants, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (161% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05874466, a study of Autism Spectrum Disorder and Autism, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
350 participants
Enrollment target
1
Study location

Study Summary

This is a pivotal, prospective, double-blind, study to evaluate the sensitivity and specificity of the SenseToKnow device for the detection of autism spectrum disorder in children 16-36 months of age.

Study Locations (1)

North Carolina

  • Duke University - Durham

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2023-07-07
Est. Completion 2027-12

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT05874466

The ClinicalTrials.gov registry entry for NCT05874466 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (161% higher). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.

NCT05874466 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05874466 about?

NCT05874466 is a clinical study titled "SenseToKnow Autism Screening Device Validation Study". This is a pivotal, prospective, double-blind, study to evaluate the sensitivity and specificity of the SenseToKnow device for the detection of autism spectrum disorder in children 16-36 months of age.

What is the current status of trial NCT05874466?

This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2023-07-07. Estimated completion is 2027-12.

What conditions does trial NCT05874466 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder, Autism.

Who is sponsoring clinical trial NCT05874466?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05874466 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.